#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians evaluating patients with cannabis use need to assess concurrent tobacco use as a potential synergistic risk factor for psychosis progression, particularly in vulnerable populations. This finding supports more targeted screening and counseling interventions during routine psychiatric assessments for at-risk individuals. Understanding this co-use pattern may inform clinical risk stratification and help guide preventive conversations with patients about dual substance use.
This Vanderbilt Health study examined over 1,000 individuals at clinical high risk for psychosis and found that concurrent cannabis and tobacco use significantly elevates the risk of developing psychotic disorders compared to either substance alone. The research builds on established evidence that cannabis use increases psychosis risk in vulnerable populations, but identifies a synergistic effect when tobacco co-use is present, suggesting a potential interaction between the two substances in affecting psychotic symptom emergence. For clinicians managing patients with genetic or clinical vulnerability to psychosis, these findings underscore the importance of comprehensive substance use screening that addresses both cannabis and tobacco, as well as counseling about the compounded risks of concurrent use. This is particularly relevant given that individuals at clinical high risk represent a population amenable to early intervention, where modifiable risk factors like substance use can be targeted to prevent disease progression. Clinicians should consider documenting cannabis and tobacco co-use patterns as a specific risk factor when evaluating psychosis risk in vulnerable patients, and incorporate this information into risk stratification and preventive counseling.
“We’ve known for years that cannabis can precipitate psychosis in vulnerable individuals, but this data showing that tobacco co-use significantly amplifies that risk is clinically important because most of our patients who use cannabis aren’t using it in isolation. When I’m taking a substance use history, I now specifically probe for concurrent tobacco use, because it changes my risk stratification and my counseling considerably.”
💭 This study adds to growing evidence that concurrent cannabis and tobacco use may synergistically elevate psychosis risk in vulnerable populations, beyond what either substance alone might confer. Clinicians should recognize that individuals already at clinical high risk for psychosis face compounded neurobiological effects when using multiple psychoactive substances, though disentangling the specific contribution of each substance from confounding factors like stress, sleep disruption, or social isolation remains challenging in observational research. The findings warrant more detailed substance use screening during psychiatric evaluations, particularly asking about patterns of co-use rather than assessing drugs in isolation. When counseling high-risk patients about harm reduction, providers should emphasize that combining cannabis with tobacco may carry greater psychotic risk than either substance individually, which may motivate some individuals to consider cessation or single-substance reduction strategies.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
